Oruka Therapeutics Inc.

6 days ago · marketbeat.com

Oruka Therapeutics NASDAQ: ORKA reported interim week 16 results from EVERLAST-B, a Phase IIb dose-ranging study of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The company said its 600-milligram regimen achieved complete skin clearance, measured by PASI 100, in 61% of participants at week 16, while 86% achieved PASI 90.

7 days ago · seekingalpha.com

Oruka Therapeutics, Inc. (ORKA) Discusses Interim EVERLAST-B Results for ORCA 001 in Plaque Psoriasis Transcript

7 days ago · benzinga.com

Oruka Therapeutics Inc. (NASDAQ:ORKA) on Monday reported positive Week 16 results from its EVERLAST-B Phase 2b clinical trial evaluating ORKA-001 in patients with moderate-to-severe plaque psoriasis.

8 days ago · globenewswire.com

61% PASI 100 and 86% PASI 90 in the ORKA-001 high-dose (600 mg) group, highly similar to EVERLAST-A Continued favorable safety and tolerability profile consistent with the IL-23p19 class ORKA-001 on track to advance into Phase 3 trials in 1H 2027 52-week EVERLAST-A results on track for December 2026 ORKA-002 16-week results from ORCA-SURGE Phase 2 in psoriasis on track for 1Q 2027 Management to host conference call today at 8:00 a.m. ET MENLO PARK, Calif.

8 days ago · globenewswire.com

MENLO PARK, Calif., Oct. 25, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced it will report Week 16 data for ORKA-001 from the ongoing EVERLAST-B Phase 2b trial in moderate-to-severe plaque psoriasis on Monday, October 26, 2026. Following the announcement, the company will host a conference call and webcast at 8:00 a.m. ET to discuss the results.

16 days ago · seekingalpha.com

Oruka Therapeutics is positioned as a leader in ultra-long-acting injectable treatments for psoriasis, with ORKA-001 showing class-leading efficacy. ORKA-001's PASI 100 and PASI 90 rates at Week 28 reinforce its durability, while a replicated response in the crossover cohort strengthens confidence in trial results. ORKA's $1.1B cash balance, exclusive Hypercon technology license, and pipeline breadth provide funding through BLA and strategic flexibility amid rising R&D spend.

1 month ago · zacks.com

Oruka's ORKA-001 delivers deeper psoriasis clearance at week 28, but safety disclosures may have weighed on shares despite positive efficacy data.

1 month ago · benzinga.com

Oruka Therapeutics Inc. (NASDAQ:ORKA) on Wednesday reported positive week 28 outcomes from its Phase 2a clinical trial evaluating ORKA-001 for moderate-to-severe plaque psoriasis.

1 month ago · globenewswire.com

PASI 100 increased to 71.4% and PASI 90 increased to 87.3%, despite no dosing after Week 4 Placebo crossover patients reached PASI 100 and PASI 90 rates similar to those initially dosed with ORKA-001 ORKA-001 maintained a favorable safety and tolerability profile through Week 28 52-week EVERLAST-A data for all patients expected in December 2026 16-week EVERLAST-B data expected in 4Q 2026 MENLO PARK, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced positive Week 28 results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, in moderate-to-severe plaque psoriasis.

2 months ago · zacks.com

Oruka's three-month rally reflects investor confidence in ORKA-001, with key clinical data and pipeline milestones scheduled ahead.